GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » Current Ratio

POAI (Predictive Oncology) Current Ratio : 0.62 (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Predictive Oncology's current ratio for the quarter that ended in Dec. 2024 was 0.62.

Predictive Oncology has a current ratio of 0.62. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Predictive Oncology has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Predictive Oncology's Current Ratio or its related term are showing as below:

POAI' s Current Ratio Range Over the Past 10 Years
Min: 0.07   Med: 2.1   Max: 9.09
Current: 0.62

During the past 13 years, Predictive Oncology's highest Current Ratio was 9.09. The lowest was 0.07. And the median was 2.10.

POAI's Current Ratio is ranked worse than
92.53% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 2.58 vs POAI: 0.62

Predictive Oncology Current Ratio Historical Data

The historical data trend for Predictive Oncology's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Current Ratio Chart

Predictive Oncology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 9.09 6.02 2.55 0.62

Predictive Oncology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.55 1.45 1.49 1.20 0.62

Competitive Comparison of Predictive Oncology's Current Ratio

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's Current Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Current Ratio distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Current Ratio falls into.


;
;

Predictive Oncology Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Predictive Oncology's Current Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Current Ratio (A: Dec. 2024 )=Total Current Assets (A: Dec. 2024 )/Total Current Liabilities (A: Dec. 2024 )
=2.226/3.593
=0.62

Predictive Oncology's Current Ratio for the quarter that ended in Dec. 2024 is calculated as

Current Ratio (Q: Dec. 2024 )=Total Current Assets (Q: Dec. 2024 )/Total Current Liabilities (Q: Dec. 2024 )
=2.226/3.593
=0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Predictive Oncology  (NAS:POAI) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Predictive Oncology Current Ratio Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology Business Description

Traded in Other Exchanges
N/A
Address
No.91 43rd Street, Suite 110, Pittsburgh, PA, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
Executives
Robert L Myers officer: CHIEF FINANCIAL OFFICER 4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr director 633 1ST STREET WEST, SONOMA CA 95476
Veena Rao director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr director 1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch director P O BOX 1572, PEPPERELL MA 01463
Pamela Bush officer: Chief Business Officer 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley director 1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith director 151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle director 1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz 10 percent owner 20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel director 900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121